Loading...
Bilateral Trade Intelligence · $214.5K Total Trade · 3 Foreign Suppliers · 3 Indian Buyers · DGFT Verified · Updated March 2026
India imported $214.5K worth of pharmaceutical formulations from Iraq across 14 verified shipments, from 3 foreign suppliers to 3 Indian buyers. The top suppliers are ALNIMAA SCIENTIFIC BUREAU ($80.2K) and AL TEAM PHARMA ($70.4K). The leading products are Ceftriaxone ($50K) and Sodium ($42K). Average shipment value: $15.3K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Ceftriaxone | $50.2K | 23.4% |
| 2 | Sodium | $41.7K | 19.4% |
| 3 | Amoxicillin | $34.2K | 15.9% |
| 4 | Dexamethasone | $30.4K | 14.2% |
| 5 | Amikacin | $16.1K | 7.5% |
| 6 | Meropenem | $14.0K | 6.5% |
| 7 | Acyclovir | $10.5K | 4.9% |
| 8 | Ondansetron | $10.0K | 4.7% |
| 9 | Hydrocortisone | $7.5K | 3.5% |
India imports 9+ pharmaceutical formulations from Iraq with a combined trade value of $214.5K. Key products include Ceftriaxone ($50K), Sodium ($42K), Amoxicillin ($34K), Dexamethasone ($30K), Amikacin ($16K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 14 verified Indian Customs (DGFT) shipment records.
3 Indian pharmaceutical companies export finished formulations to Iraq. Leading exporters include Alnimaa Scientific Bureau, Al Team Pharma, Zawraa Scientific Bureau, . The top exporter accounts for 37.4% of total India–Iraq pharma exports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Iraq and India has experienced gradual development over the past few years. Between 2022 and 2026, India imported a total of $215,000 worth of pharmaceutical formulations from Iraq, distributed across 14 shipments. This indicates a steady, albeit modest, growth in bilateral pharmaceutical trade. The average shipment value stands at approximately $15,000, reflecting a consistent demand for specific pharmaceutical products. The trade involves three foreign suppliers from Iraq and three Indian buyers, suggesting a balanced and collaborative trading environment.
Iraq's contribution to India's pharmaceutical imports remains relatively small. The total import value of $215,000 over four years accounts for a minor fraction of India's overall pharmaceutical imports. The primary categories imported from Iraq include antibiotics, corticosteroids, and antiviral medications, indicating a focus on essential therapeutic areas. This limited volume suggests that while Iraq plays a role in supplying certain pharmaceutical products to India, it is not a major contributor in the broader context of India's pharmaceutical import landscape.
These are the top pharmaceutical products exported from India to Iraq, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Iraq buyers, regulatory requirements, and logistics for that specific product corridor. Products include Ceftriaxone ($50K), Sodium ($42K), Amoxicillin ($34K), Dexamethasone ($30K), Amikacin ($16K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
3 companies in Iraq import pharmaceutical formulations from India. Top buyers include Lyka Labs Limited, Joinhub Pharma Llp, Swiss Parenterals Limited, . The largest buyer accounts for 37.4% of India–Iraq pharma imports. Source: Indian Customs (DGFT).
Between 2024 and 2026, there have been no significant policy changes or trade agreements between India and Iraq specifically affecting pharmaceutical imports. The Central Drugs Standard Control Organisation (CDSCO) has maintained its existing regulatory framework for the importation of pharmaceutical products, ensuring consistent standards and procedures. There have been no notable developments in regulatory harmonization between the two countries during this period.
Registration process, GMP requirements, import documentation
Iraqi pharmaceutical companies seeking to export products to India must navigate the CDSCO registration process. This involves appointing an Authorized Indian Representative (AIR) to act as an intermediary between the foreign manufacturer and Indian authorities. The AIR is responsible for submitting the Integrated Registration Form (IRF) through the CDSCO's SUGAM portal, which requires detailed information about the manufacturer, product, and manufacturing processes. Key documents include a Site Master File, Plant Master File, and a Free Sale Certificate from the country of origin. The registration process is comprehensive, ensuring that imported pharmaceutical products meet India's safety, efficacy, and quality standards.
India requires that foreign manufacturing sites adhere to Good Manufacturing Practice (GMP) standards as outlined by the World Health Organization (WHO). Iraqi manufacturers must obtain a GMP certificate from the National Drug Regulatory Authority, demonstrating compliance with these international standards. The CDSCO may conduct inspections to verify adherence to GMP guidelines, ensuring that imported pharmaceutical products are manufactured under conditions that guarantee their quality and safety.
To import pharmaceutical products into India, Iraqi companies must provide several key documents:
These documents facilitate the customs clearance process and ensure that imported pharmaceutical products comply with Indian regulations.
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical products imported from Iraq to India primarily consist of antibiotics, corticosteroids, and antiviral medications. Notably, ceftriaxone, an antibiotic, leads the imports with a value of $50,000, accounting for 23.4% of the total import value. Other significant imports include sodium-based products ($42,000, 19.4%), amoxicillin ($34,000, 15.9%), and dexamethasone ($30,000, 14.2%). These products are essential in treating a range of infections and inflammatory conditions, indicating a demand for such medications in the Indian market.
The imports from Iraq to India do not prominently feature innovator drugs, novel formulations, or advanced therapies. The focus remains on essential pharmaceutical products that are widely used and have established efficacy. This suggests that while Iraq contributes to meeting the demand for standard pharmaceutical products in India, it does not significantly supply cutting-edge or specialized medical treatments.
India's importation of pharmaceutical products from Iraq is driven by several factors:
These factors collectively influence India's decision to import pharmaceutical products from Iraq, aiming to meet the healthcare demands of its population.
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes the following components:
These tariffs and taxes collectively impact the pricing and competitiveness of imported pharmaceutical products in the Indian market.
As of March 2026, there are no specific Free Trade Agreements (FTAs) between India and Iraq that offer preferential duty rates for pharmaceutical imports. India's participation in regional trade agreements, such as the Regional Comprehensive Economic Partnership (RCEP), does not currently include Iraq, limiting the scope for preferential trade terms in the pharmaceutical sector.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents by ensuring that only genuine innovations receive patent protection. This policy can impact the availability of generic versions of patented drugs. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential medicines, including imported drugs, to ensure affordability. Compulsory licensing provisions allow the government to grant licenses to produce patented drugs without the consent of the patent holder under specific circumstances, such as public health emergencies.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Iraq to India primarily utilize sea routes, with major ports in Iraq such as Umm Qasr serving as departure points. These shipments typically transit through the Arabian Sea, entering India via ports like Mumbai and Chennai. The transit time for sea shipments ranges from 15 to 30 days, depending on the specific ports and shipping lines used. Air freight options are also available, offering faster delivery times but at higher costs.
In Iraq, the Umm Qasr Port is the primary export hub for pharmaceutical products, equipped with facilities to handle bulk and containerized cargo. In India, major import ports such as Mumbai, Chennai, and Kolkata are equipped to handle pharmaceutical shipments, with dedicated facilities for customs clearance and quality inspections. These ports are well-connected and capable of efficiently processing pharmaceutical imports.
Upon arrival at Indian ports, pharmaceutical imports undergo customs clearance, which includes verification of import documentation and compliance with CDSCO regulations. The CDSCO conducts quality testing to ensure that imported pharmaceutical products meet Indian standards. Cold chain management is critical for temperature-sensitive products, and Indian ports are equipped with refrigerated storage facilities to maintain the required conditions. Good Distribution Practice (GDP) compliance is mandatory, ensuring that pharmaceutical products are stored and transported under conditions that maintain their quality and efficacy.
Market size, healthcare system, growth outlook
Despite being a major manufacturer of pharmaceuticals, India imports certain products from Iraq due to factors such as patent protection, technology gaps, and the need to meet specific quality requirements. Imported products may offer cost-effective alternatives to domestically produced drugs, especially in the case of generics. Additionally, the importation of certain pharmaceutical products addresses specific healthcare needs
India exported pharmaceuticals worth $214.5K to Iraq across 14 verified shipments.
1. ALNIMAA SCIENTIFIC BUREAU — $80.2K. 2. AL TEAM PHARMA — $70.4K. 3. ZAWRAA SCIENTIFIC BUREAU — $63.9K. Total: 3 suppliers.
1. LYKA LABS LIMITED — $80.2K. 2. JOINHUB PHARMA LLP — $70.4K. 3. SWISS PARENTERALS LIMITED — $63.9K. 3 buyers total.
1. Ceftriaxone ($50.2K, 23.4%); 2. Sodium ($41.7K, 19.4%); 3. Amoxicillin ($34.2K, 15.9%); 4. Dexamethasone ($30.4K, 14.2%); 5. Amikacin ($16.1K, 7.5%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $214.5K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$15.3K per consignment across 14 shipments.
3 Indian companies. Largest: ALNIMAA SCIENTIFIC BUREAU with $80.2K.
TransData Nexus covers 3 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 14 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Exporters
3 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists